Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.

Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S; RIO-Europe Study Group.

Lancet. 2005 Apr 16-22;365(9468):1389-97. Erratum in: Lancet. 2005 Jul 30-Aug 5;366(9483):370.

2.

[The endocannabinoid system, overweight, and the CB1-endocannabinoid-receptor antagonist rimonabant].

Boekholdt SM, Jukema JW, Peters RJ.

Ned Tijdschr Geneeskd. 2007 Nov 24;151(47):2615-9. Review. Dutch.

PMID:
18161262
3.

CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.

Scheen AJ.

J Neuroendocrinol. 2008 May;20 Suppl 1:139-46. doi: 10.1111/j.1365-2826.2008.01681.x. Review.

4.

An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity.

Christopoulou FD, Kiortsis DN.

J Clin Pharm Ther. 2011 Feb;36(1):10-8. doi: 10.1111/j.1365-2710.2010.01164.x. Review.

PMID:
21198716
5.

The role of endocannabinoid system blockade in the treatment of the metabolic syndrome.

Kakafika AI, Mikhailidis DP, Karagiannis A, Athyros VG.

J Clin Pharmacol. 2007 May;47(5):642-52. Epub 2007 Mar 28. Review.

PMID:
17392496
6.

Rimonabant for overweight or obesity.

Curioni C, André C.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD006162. Review.

PMID:
17054276
7.
8.

What is the potential role of cannabinoid-1 receptor blockade in glucose and lipid management?

Jensen MD.

Am J Med. 2007 Sep;120(9 Suppl 1):S25-31; discussion S31-2. Review.

PMID:
17720358
9.

Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: safety, tolerability, and therapeutic potential.

Steinberg BA, Cannon CP.

Am J Cardiol. 2007 Dec 17;100(12A):27P-32P. Review.

PMID:
18154743
10.
11.

[Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system].

Ducobu J, Sternon J.

J Pharm Belg. 2005;60(3):89-91. Review. French.

PMID:
16252510
12.

Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: efficacy.

Aronne LJ, Isoldi KK.

Am J Cardiol. 2007 Dec 17;100(12A):18P-26P. Review.

PMID:
18154742
13.

[Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies].

Scheen AJ, Van Gaal LG, Després JP, Pi-Sunyer X, Golay A, Hanotin C.

Rev Med Suisse. 2006 Aug 23;2(76):1916-23. Review. French.

PMID:
16972542
14.

The endocannabinoid system as a novel approach for managing obesity.

Lillo JL.

J Am Osteopath Assoc. 2007 Apr;107(4 Suppl 2):S12-20. Review.

PMID:
17784530
15.

Rimonabant: endocannabinoid inhibition for the metabolic syndrome.

Wierzbicki AS.

Int J Clin Pract. 2006 Dec;60(12):1697-706. Review. Erratum in: Int J Clin Pract. 2007 Mar;61(3):534.

PMID:
17109677
17.

Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors.

Gelfand EV, Cannon CP.

J Am Coll Cardiol. 2006 May 16;47(10):1919-26. Epub 2006 Apr 24. Review.

18.

Rimonabant: new data and emerging experience.

Wright SM, Dikkers C, Aronne LJ.

Curr Atheroscler Rep. 2008 Feb;10(1):71-8. Review.

PMID:
18366988
19.

The endocannabinoid system and cardiometabolic risk: effects of CB1 receptor blockade on lipid metabolism.

Deedwania P.

Int J Cardiol. 2009 Jan 24;131(3):305-12. doi: 10.1016/j.ijcard.2008.06.033. Epub 2008 Aug 19. Review.

PMID:
18715660
20.

Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders.

Scheen AJ, Paquot N.

Best Pract Res Clin Endocrinol Metab. 2009 Feb;23(1):103-16. doi: 10.1016/j.beem.2008.09.001. Review.

PMID:
19285264

Supplemental Content

Support Center